Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses Authorization based on data including an ongoing pivotal Phase 3 trial conducted in the U.K. with almost 15,000 participants GAITHERSBURG, Md., Feb. 3, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older in Great Britain.

Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*

NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a buy yet. The post Avoid Novavax for Now, Until the Picture Clears Up appeared first on InvestorPlace.

Avoid Novavax for Now, Until the Picture Clears Up

The biotech hasn't been in the best shape lately.

Will Novavax Hit $250 This Year?

In the wake of a multitude of positive press releases, NVAX stock traders should prepare for an imminent bounce in the share price. The post Novavax Should Move Higher After International Distribution Efforts appeared first on InvestorPlace.

Novavax Should Move Higher After International Distribution Efforts

Marathon Digital Holdings

Pinterest

PayPal

Shopify

Cheap stocks to buy that also have a robust growth visibility for the coming years. Stocks to consider in the current market correction.

7 Great Cheap Stocks to Buy for Solid Growth in 2022

After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.

Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab

The company requested U.S. Emergency Use Authorization (EUA) for its COVID-19 vaccine.

Why Novavax Stock Is Rising Today

American Airlines

Palo Alto Networks

Block

Target

Workday

In these inflationary times, analysts predict robust earnings growth especially in old economy stocks. Here are seven names to consider.

7 Stocks to Watch in This Current Earnings Season

The company was one of investors' early favorites in the vaccine race.

After Dropping 40%, Is Novavax a Buy?

Novavax, Inc. NVAX shares are trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. Novavax was up 13% at $93.70 Monday afternoon at publication.

Is Novavax Turning Around? A Technical Analysis

Novavax's coronavirus vaccine relies on traditional protein-based technology rather than newer mRNA technology, and was extremely effective at preventing serious Covid-19 symptoms in clinical trials.

Novavax Asks FDA To Authorize Its Non-MRNA Covid Vaccine

Today, investors in Novavax and NVAX stock got the news they were hoping for: the company announced an application with the FDA. The post NVAX Stock Alert: The HUGE Reason Novavax Is Shooting Higher Today appeared first on InvestorPlace.

NVAX Stock Alert: The HUGE Reason Novavax Is Shooting Higher Today

Novavax Inc (NASDAQ: NVAX) is trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. Novavax's submission includes the results from two large pivotal clinical trials which demonstrated approximately 90% overall efficacy.

Why Novavax Shares Are Rising Today

Novavax has lagged in the vaccine delivery race, but is finally ready to delivery. The post Novavax: The Fall of a Covid-19 Vaccine Star appeared first on InvestorPlace.

Novavax: The Fall of a Covid-19 Vaccine Star

Shares of Novavax Inc. NVAX, +8.37% rallied 10.0% in trading on Monday after the company said it filed for authorization of its experimental COVID-19 shot in the U.S. Novavax's COVID-19 vaccine candidate is protein-based, meaning it's a different type of vaccine than the mRNA shots developed by BioNTech SE BNTX, +5.00% /Pfizer Inc. PFE, -2.60% and Moderna Inc. MRNA, +5.34% or the Johnson & Johnson JNJ, +0.48% viral vector vaccine. Novavax said it is seeking authorization for its two-dose vaccine in adults, based on two clinical studies.

Novavax asks the FDA to authorize its COVID-19 vaccine candidate

Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.

Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel

- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Jan. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2.

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Its latest earnings report could provide insight for investors.

Will Novavax's New Covid Vaccine Impact Its Stock?

Its shares can't stay in free fall forever. Or can they?

What's Next For Novavax Stock?

The company signs a new supply deal as news emerges of the latest coronavirus variant.

Why Novavax Stock Surged 14% on Friday

If Novavax gets finally its Emergency Use Authorization next month from the FDA, then you can expect NVAX stock to skyrocket. The post Novavax Could Be the Biggest Bargain in the Market Right Now appeared first on InvestorPlace.

Novavax Could Be the Biggest Bargain in the Market Right Now

Israel's Ministry of Health has agreed to purchase Novavax Inc's NVAX protein-based COVID-19 vaccine candidate, NVX-CoV2373. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.

Israel Inks COVID-19 Vaccine Deal With Novavax

Novavax, Inc. (NASDAQ:NVAX ) was last seen up 1.6% at $74.25, after Israel inked a deal with the biotechnology concern to buy 5 million of its Covid-19 vaccine doses.

Novavax Inks Lofty Covid-19 Vaccine Deal with Israel

Novavax said it's on track to make 200 million doses per month by March. In early January, the Serum Institute had already made 200 million Novavax doses. A consortium says over 18 billion high-quality vaccine doses are likely needed in 2022. Novavax says, excluding China and Russia and children under 12, about 11.6 billion doses are needed.

Novavax Marches Ahead With Several Positive, Major Developments

Novavax Inc. NVAX, -7.91% said Friday it will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. "Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval," the company said in a statement.

News for Novavax Stock (NVAX)